May be the first new chemical entity developed and marketed by an Indian company.

Malvinder singhSix years after the Geneva-based, not-for-profit organisation, Medicines for Malaria Venture (MMV), made Ranbaxy its drug development partner, the latter today announced the start of final-stage clinical trials for a new anti-malaria drug.

New Delhi, May 4 Ranbaxy Laboratories Ltd on Monday announced the commencement of the third phase clinical trials for its new anti-malaria combination drug in India, Bangladesh and Thailand.

PB Jayakumar / Mumbai May 2, 2009, 0:14 IST

Tokyo's policy push for generics an added draw.

Leading Indian drug makers such as Ranbaxy, Lupin, Zydus Cadila and Dishman, which forayed into Japan in the past three years, have emerged as important players in the generic or copycat drug business of patented medicines in that market, the second largest in the world.

PAWAN BALI

The spread of Swine flu is likely to boost the sales of companies like Cipla, which can provide drugs and vaccines for this deadly disease.

Ms Sarabjit Kaur Nagra, pharma analyst with Angel Broking said that Cipla and Ranbaxy are the two Indian companies, which can provide drugs to deal with Swine flu.

Ranbaxy Laboratories

Pharma Firm

New Delhi: Ranbaxy announced on Friday that it has received approval from Australia

Joe C Mathew / New Delhi March 06, 2009, 0:37 IST

DAIICHI Sankyo, the new owner of India

After the US, New Zealand alert indian drug manufacturer Ranbaxy Laboratories